

CC-115, a dual inhibitor of mTOR kinase and DNA-PK, b
selectively inhibits ATM-deficient cell growth *in vitro*

Oncotarget

8, 74688-74702

DOI: [10.18632/oncotarget.20342](https://doi.org/10.18632/oncotarget.20342)

Citation Report

#	ARTICLE	IF	CITATIONS
1	mTORC1 pathway in DNA damage response. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2018, 1865, 1293-1311.	1.9	97
2	Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies. <i>Clinical Cancer Research</i> , 2019, 25, 5623-5637.	3.2	23
3	AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity. <i>Nature Communications</i> , 2019, 10, 5065.	5.8	195
4	BDE-209 induces male reproductive toxicity via cell cycle arrest and apoptosis mediated by DNA damage response signaling pathways. <i>Environmental Pollution</i> , 2019, 255, 113097.	3.7	34
5	EFTs meet Higgs nonlinearity, compositeness and (neutral) naturalness. <i>Journal of High Energy Physics</i> , 2019, 2019, 1.	1.6	13
6	Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 2257-2269.	0.8	135
7	CC-115, a Dual Mammalian Target of Rapamycin/DNA-Dependent Protein Kinase Inhibitor in Clinical Trial, Is a Substrate of ATP-Binding Cassette G2, a Risk Factor for CC-115 Resistance. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 371, 320-326.	1.3	7
8	PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5792.	1.8	65
9	<p>First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 10463-10476.	0.9	56
10	Targeting the DNA-PK complex: Its rationale use in cancer and HIV-1 infection. <i>Biochemical Pharmacology</i> , 2019, 160, 80-91.	2.0	15
11	Synthetic Lethality through the Lens of Medicinal Chemistry. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 14151-14183.	2.9	31
12	Senescence Induction by Combined Ionizing Radiation and DNA Damage Response Inhibitors in Head and Neck Squamous Cell Carcinoma Cells. <i>Cells</i> , 2020, 9, 2012.	1.8	19
13	Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy. <i>Cells</i> , 2020, 9, 2110.	1.8	17
14	Dual mTOR/DNA-PK Inhibitor CC-115 Induces Cell Death in Melanoma Cells and Has Radiosensitizing Potential. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9321.	1.8	15
15	Novel therapeutic strategies for MLL-rearranged leukemias. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2020, 1863, 194584.	0.9	8
16	Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR. <i>Journal of Oncology</i> , 2020, 2020, 1-11.	0.6	125
17	DNA-PK in human malignant disorders: Mechanisms and implications for pharmacological interventions. , 2020, 215, 107617.		27
18	Jianpi-yangwei decoction inhibits DNA damage repair in the drug resistance of gastric cancer by reducing FEN1 expression. <i>BMC Complementary Medicine and Therapies</i> , 2020, 20, 196.	1.2	10

#	ARTICLE	IF	CITATIONS
19	Targeting DNA-PK in cancer. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2020, 821, 111692.	0.4	48
20	DNA-PKcs chemical inhibition versus genetic mutation: Impact on the junctional repair steps of V(D)J recombination. Molecular Immunology, 2020, 120, 93-100.	1.0	15
21	Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: Still a potential druggable target?. Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118731.	1.9	51
22	Small molecule DNA-PK inhibitors as potential cancer therapy: a patent review (2010â€“present). Expert Opinion on Therapeutic Patents, 2021, 31, 435-452.	2.4	37
23	Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer. Gut, 2021, 70, 743-760.	6.1	49
24	Exploiting DNA repair pathways for tumor sensitization, mitigation of resistance, and normal tissue protection in radiotherapy. , 2021, 4, 244-263.		14
25	DNA damage repair in glioblastoma: current perspectives on its role in tumour progression, treatment resistance and PIKking potential therapeutic targets. Cellular Oncology (Dordrecht), 2021, 44, 961-981.	2.1	10
26	Exploiting DNA Damage Repair in Precision Cancer Therapy: BRCA1 as a Prime Therapeutic Target. Cancers, 2021, 13, 3438.	1.7	11
27	Inhibition of DNA damage response pathway using combination of DDR pathway inhibitors and radiation in treatment of acute lymphoblastic leukemia cells. Future Oncology, 2021, 17, 2803-2816.	1.1	4
28	Drug Repurposing for Targeting Acute Leukemia With KMT2A (MLL)â€“Gene Rearrangements. Frontiers in Pharmacology, 2021, 12, 741413.	1.6	8
29	Druggable binding sites in the multicomponent assemblies that characterise DNA double-strand-break repair through non-homologous end joining. Essays in Biochemistry, 2020, 64, 791-806.	2.1	6
30	Dual inhibition of DNA-PKcs and mTOR by CC-115 potently inhibits human renal cell carcinoma cell growth. Aging, 2020, 12, 20445-20456.	1.4	2
31	Dual inhibition of DNA-PKcs and mTOR by CC-115 potently inhibits human renal cell carcinoma cell growth. Aging, 2020, 12, 20445-20456.	1.4	7
32	Antiâ€“tumoural activity of the Gâ€“quadruplex ligand pyridostatin against BRCA1/2â€“deficient tumours. EMBO Molecular Medicine, 2022, 14, e14501.	3.3	13
33	Therapeutic Targeting of DNA Damage Response in Cancer. International Journal of Molecular Sciences, 2022, 23, 1701.	1.8	26
34	The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases. Molecular Cancer Therapeutics, 2022, 21, 555-567.	1.9	11
35	Perspective on the Use of DNA Repair Inhibitors as a Tool for Imaging and Radionuclide Therapy of Glioblastoma. Cancers, 2022, 14, 1821.	1.7	3
36	Targeting DNA repair pathway in cancer: Mechanisms and clinical application. MedComm, 2021, 2, 654-691.	3.1	34

#	ARTICLE	IF	CITATIONS
37	Development and Evolution of DNA-Dependent Protein Kinase Inhibitors toward Cancer Therapy. International Journal of Molecular Sciences, 2022, 23, 4264.	1.8	12
38	Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma. Molecular Cancer Therapeutics, 2022, 21, 1381-1392.	1.9	0
39	An mTOR and DNA-PK dual inhibitor CC-115 hinders non-small cell lung cancer cell growth. Cell Death Discovery, 2022, 8, .	2.0	4
40	Novel Treatments of Uveal Melanoma Identified with a Synthetic Lethal CRISPR/Cas9 Screen. Cancers, 2022, 14, 3186.	1.7	2
42	<scp>SMG1</scp>, a nonsense-mediated <scp>mRNA</scp> decay (<scp>NMD</scp>) regulator, as a candidate therapeutic target in multiple myeloma. Molecular Oncology, 2023, 17, 284-297.	2.1	2
43	Targeting the DNA Damage Response Machinery for Lung Cancer Treatment. Pharmaceuticals, 2022, 15, 1475.	1.7	6
44	DNA-PK hyperactivation occurs in deletion 11q chronic lymphocytic leukemia and is both a biomarker and therapeutic target for drug-resistant disease. Blood Cancer Journal, 2023, 13, .	2.8	1